A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD4916 Following Single- and Multiple-ascending-dose Administration to Healthy Adult Volunteers (Including Japanese and Chinese Healthy Volunteers)
Latest Information Update: 07 May 2025
At a glance
- Drugs AZD 4916 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 07 May 2025 New trial record